Article Text

other Versions

CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma
  1. Qi-Xing Gong1,
  2. Zhen Wang1,
  3. Chong Liu1,
  4. Xiao Li1,
  5. Ting-Xun Lu2,
  6. Jin-Hua Liang2,
  7. Wei Xu2,
  8. Jian-Yong Li2,
  9. Zhi-Hong Zhang1
  1. 1Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  2. 2Department of Haematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  1. Correspondence to Professor Zhi-Hong Zhang, Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; zhangzhih2001{at} and Jian-Yong Li, Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; lijianyonglm{at}


Aim CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.

Methods A total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.

Results Using a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.

Conclusion CD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.

  • lymphoma
  • immunophenotyping
  • fish

Statistics from


  • Handling editor Mary Frances McMullin.

  • Contributors Q-XG, Z-HZ and J-YL designed the experiment. Q-XG and ZW re-evaluated the HE slides of all the de novo DLBCL cases. Q-XG and T-XL performed immunohistochemical staining and evaluated the signals. XL carried out the FISH experiments. J-HL, WX and J-YL organised the clinical materials. CL carried out the data analysis and Q-XG wrote the manuscript.

  • Funding This work was supported in part by grants from the National Natural Science Foundation of China (81773109), the National Scientific Foundation of Jiangsu Provincial of China (BK20151582), National key Clinical Specialty Construction Project (2014), and the Fund of the priority Academic Program Development of Jiangsu Higher Education Institution (JX10231801).

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval The ethics committee of the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.